Eldepryl (selegiline HCl)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Selegiline hydrochloride, a propargyl amphetamine derivative, is a selective and irreversible inhibitor of monoamine oxidase-B (MAO-B).
USES: This medication is used to treat movement disorders caused by Parkinson's disease. It does not cure Parkinson's disease, but it may improve shakiness (tremor), muscle stiffness, loss of normal movement as your dose of other Parkinson's medication wears off (end-of-dose failure), and sudden switching between normal movement and stiffness ("on-off" problems). It may improve your range of motion and ability to walk, dress, and exercise.
Selegiline is usually used in combination with other medicines (such as levodopa, carbidopa). Selegiline is an enzyme blocker (MAO inhibitor) that works by slowing the breakdown of certain natural substances in the brain (neurotransmitters such as dopamine, norepinephrine, and serotonin).
Generic name: selegiline HCl
Pronunciation: (seh-LEDGE-uh-leen)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Eldepryl
Indications
The following indications are listed for Eldepryl:
- Idiopathic Parkinsonism
Also known as: Paralysis Agitans, Primary Parkinson's Disease.
Dosing
Dosage of selegiline hydrochloride is expressed in terms of the salt.
Selegiline hydrochloride is administered orally as conventional tablets, capsules, or orally disintegrating tablets for the management of parkinsonian syndrome.
Conventional oral preparations of the drug are administered in 2 equally divided doses daily with breakfast and lunch.
Selegiline orally disintegrating tablets (Zelapar(R)) should be administered once daily in the morning before breakfast. Patients should avoid ingesting any foods or liquids for 5 minutes prior to and after administration of the tablets. The orally disintegrating tablets should not be removed from their original packaging (blister packs) until just prior to administration. With dry hands, the backing of 1 or 2 blisters (depending on dosage) should be peeled open; the tablet(s) should be gently removed and placed immediately on the tongue where dissolution occurs in seconds. (See Pharmacokinetics: Absorption.)
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
No enhanced messaging available.
Reproduction studies in rats given oral selegiline hydrochloride dosages of 4, 12, or 36 mg/mg (4, 12, or 35 times the human therapeutic dose on a mg/m2 basis) have not revealed teratogenic effects. However, there was a decrease in fetal body weight at the highest dose evaluated. In a perinatal and postnatal development study in rats given oral dosages of 4, 16, or 64 mg/kg (4, 15, or 62 times the human therapeutic dose on a mg/m2 basis), an increase in the number of stillbirths and a decrease in the number of pups per dam, pup survival, and pup weight (at birth and throughout the lactation period) occurred at the two highest dosage levels. Because none of the pups born alive survived to day 4 postpartum at the highest dose, postnatal development of these pups could not be evaluated.
Reproduction studies in rabbits given oral selegiline hydrochloride dosages of 5, 25, or 50 mg/kg (10, 48, or 95 times the human therapeutic dose on a mg/m2 basis) have not revealed teratogenic effects; however, the number of litters produced at the 2 highest dosage levels was lower than that recommended for assessment of teratogenic potential. An increase in total resorptions and percent postimplantation loss, and a decrease in the number of live fetuses per dam was observed at the highest dose level.
There are no adequate and controlled studies to date using selegiline in pregnant women, and the drug should be used during pregnancy only when the potential benefits justify the possible risks to the fetus.
It is not known whether selegiline is distributed into human milk; the drug is distributed into milk in rats. Because many drugs are distributed into human milk, selegiline should be used with caution in nursing women. Some manufacturers state that consideration should be given to discontinuing the use of all but absolutely essential drug therapy in nursing women.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.